Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470145 · ClinicalTrials.gov registry record · Phase 1
Comparison Of Two Tablet Formulations Of SB-568859
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00470145 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT00470145, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug depending on how the study drug is made. This study will compare SB-568859 tablets that are made in 2 different ways. This is not a treatment study.
Interventions
- DRUG SB-568859
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470145
The ClinicalTrials.gov registry entry for NCT00470145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-568859 is the first listed.
NCT00470145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470145 about?
NCT00470145 is a clinical study titled "Comparison Of Two Tablet Formulations Of SB-568859". SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug depending on how the study drug is made. This study will compare SB-568859 ta...
What is the current status of trial NCT00470145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00470145?
The interventions under investigation include: SB-568859 (DRUG).
Who is sponsoring clinical trial NCT00470145?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.